ATLANTA, GA – – (Newsfile Corp. – November 11, 2020) – – Holzer & Holzer, LLC is investigating whether Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) complied with federal securities laws. Trading in Biogen was halted on November 6, 2020, in advance of the Company’s meeting with the FDA. On the same day, Bloomberg reported in an article titled “Biogen Alzheimer’s Drug Fails to Gain FDA Panel’s Backing,” that “the outside experts voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was insufficient to show Biogen’s drug works.” According to the article, the experts “also voted 10 to 0, with 1 undecided, that the positive study shouldn’t be considered primary proof the drug works in light of conflicting evidence from a different trial.” The price of Biogen’s stock fell following the announcement. If you purchased shares of Biogen and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.